Johnson & Johnson
J

Management and Proactive Care of Adverse Events Associated with Locally Advanced or Metastatic EGFR+ NSCLC Treatment

By Johnson & Johnson FEATURING Joshua K. Sabari, Alexander Spira
By Johnson & Johnson FEATURING Joshua K. Sabari, Alexander Spira
67 views
May 21, 2024
Comments are disabled for this content.

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Related Content

AUTOPLAY
06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse
09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

35:40
Balazs Halmos

Year in Review: Lung Cancer

57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
27:04
Fengting Yan

Cancer Screening Molecular Tools

11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
07:43
Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
14:49
Vivek Subbiah

Year in Review: Precision Medicine

29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
20:52
Total Health

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Feat. T. Boyle
21:24
Chul Kim

ADCs and Bispecific Inhibitors in NSCLC

16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
02:41
GRACE

Staging Disease: How Oncologists Stage NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang
08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
05:02
GRACE

Targeted Therapies in Lung Cancer 2023: Biomarkers in NSCLC

Feat. A. Desai